2 en premier auteur

1. Vergely I., Okochi V., Golpayegani S., Reboud-Ravaux M., Kobaiter R., Joyeau R. et Wakselman M., 1995, «Inhibition of human leukocyte elastase by functionalized N-aryl azetidin-2-ones: substituent effects at C-3 and benzylic positions», Eur. J. Med. Chem., 30, p. 199-208.
   
    
2. Vergely I., Laugaa P. et Reboud-Ravaux M., 1996, «Interaction of human leukocyte elastase with a N-aryl azetidinone suicide substrate: Conformational analyses based on the mechanism of action of serine proteinases», J. Mol. Graph., 14, p. 158-167 & p.145.
   
    

9 en co-auteur

1. Vilain A.-C., Okochi V., Vergely I., Reboud-Ravaux M., Mazaleyrat J.-P. et Wakselman M., 1991, «Acyloxybenzyl halides, inhibitors of elastases», Biochim. Biophys. Acta, 1076, p. 401-405.
   
    
2. Wakselman M., Joyeau R., Kobaiter R., Boggetto N., Vergely I., Maillard J., Okochi V., Montagne J.-J. et Reboud-Ravaux M., 1991, «Functionalized N-aryl azetidinones as novel mechanism-based inhibitors of neutrophil elastase», FEBS Lett., 282, p. 377-381.
   
    
3. Reboud-Ravaux M., Vergely I., Maillard J., Favreau C., Kobaiter R., Joyeau R. et Wakselman M., 1992, «Prevention of some types of inflammatory damage using AA 231-1, a fluorinated β-lactam», Drugs Exp. Clin. Res., 18, p. 159-162.
   
    
4. Maillard J.-L., Favreau C., Vergely I., Reboud-Ravaux M., Joyeau R., Kobaiter R. et Wakselman M., 1992, «Protection of vascular basement membrane and microcirculation from elastase-induced damage with a fluorinated β-lactam derivative», Clin. Chim. Acta, 213, p. 75-86.
   
    
5. Vilain A.-C., Pirotte B., Vergely I., Boggetto N., Masereel B., Schynts M., Delarge J. et Reboud-Ravaux M., 1993, «Evaluation of the inhibitory activity on serine and aspartic proteases of 4-amino-4H-1,2,4-triazole and 5-aminothiazole derivatives structurally related to β-lactam antibiotics», J. Pharm. Pharmacol., 45, p. 466-472.
   
    
6. Reboud-Ravaux M.-C., Boggetto N.-D., Doucet C.-E., de Rosny E.-H., Vergely I.-B. , Thierry N.-M. et Amour A.-J., 1996, «Synthetic inhibitors targeting serine and aspartic acid proteases»(Article en français), J. Pharm. Belg., 51, p. 161-164.
   
    
7. Joyeau R., Felk A., Guilaume S., Wakselman M., Vergely I., Doucet C., Boggetto N. et Reboud-Ravaux M., 1996, «Synthesis and inhibition of human leucocyte elastase by functionalized N-aryl azetidin-2-ones: effect of different substituents on the aromatic ring», J. Pharm. Pharmacol., 48, p. 1218-1230.
   
    
8. Doucet C., Vergely I., Reboud-Ravaux M., Guilhem J., Kobaiter R., Joyeau R. et Wakselman M., 1997, «Inhibition of human leukocyte elastase by functionalized N-aryl-3,3-dihalogenoazetidin-2-ones. Stereospecific synthesis and chiral recognition of dissymmetrically C3-substituted β-lactams», Tetrahedron Asymmetry, 8, p. 739-751.
   
    
9. Qasmi D., de Rosny E., Rene L., Badet B., Vergely I., Boggetto N. et Reboud-Ravaux M., 1997, «Synthesis of N-glyoxylyl peptides and their in vitro evaluation as HIV-1 protease inhibitors», Bioorg. Med. Chem., 5, p. 707-714.
   
    

2 en tant que collaborateur

1. Pochet L., Doucet C., Schynts M., Thierry N., Boggetto N., Pirotte B., Jiang K. Y., Masereel B., de Tullio P., Delarge J. et Reboud-Ravaux M. 1996, «Esters and amides of 6-(chloromethyl)-2-oxo-2H-1-benzopyran-3-carboxylic acid as inhibitors of α-chymotrypsin: significance of the "aromatic" nature of the novel ester-type coumarin for strong inhibitory activity», J. Med. Chem., 39, p. 2579-2585.
   
    
2. Pible O., Guilbaud P., Pellequer J. L., Vidaud C. et Quéméneur E., 2006, «Structural insights into protein–uranyl interaction: towards an in silico detection method», Biochimie, 88, p. 1631-1638.